U.S. Markets close in 37 mins

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.10+0.49 (+2.38%)
As of 04:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.61
Bid15.00 x 800
Ask29.20 x 800
Day's Range19.97 - 21.14
52 Week Range19.97 - 62.16
Avg. Volume587,760
Market Cap1.146B
Beta (5Y Monthly)1.44
PE Ratio (TTM)0.85
EPS (TTM)24.95
Earnings DateApr 27, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.80
  • Benzinga

    Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff

    Agios Pharmaceuticals Inc (NASDAQ: AGIO) will be letting go of 50 employees and shuffling its R&D leadership team to focus internal research efforts on its lead programs. Chief Medical Officer Sarah Gheuens will assume the role of R&D and Chief Scientific Officer at the end of July. Agios' chief scientific officer, Bruce Car, will step down from the role and remain with the company through July to facilitate the transition. The changes will unlock about $40 million to $50 million in cost savings

  • GlobeNewswire

    Agios Announces Evolution of Research Organization

    – Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July – – Company to Focus Internal Research Efforts on Late Lead-Optimization Programs, Including PAH Stabilizers and BCAT2 Inhibitors, and Prioritize In-Licensing or Acquiring Promising, Well-Characterized Assets for Pipeline Growth – – Expected to Deliver Annual Average Cost Savings of $40-50 Million Starting in 2023 – CAMBRIDGE, Mass., May 16, 2022 (GLOBE

  • American City Business Journals

    Agios to lay off 50 as it sets its sights on later-stage drugs

    Agios Pharmaceuticals Inc. is laying off about half of its research and development team, about 50 people, as it homes in on later-stage drug candidates.